No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The company's Yunnan blood product factory has been completed and is currently pushing forward various process works.
On December 23, Glonghui reported that Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interaction platform that the Yunnan blood product factory has been completed. The company is currently advancing the product process validation, changes in the pharmaceutical marketing authorization holder, production site and pharmaceutical research, and change approvals in accordance with the "Measures for the Administration of Changes After Drug Marketing" and other relevant normative documents and technical guidance principles. The company is currently unable to accurately predict the completion time for all processes and the specific start time for production.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Currently, there are no food safety-related testing products available.
On November 29, Gelonghui reported that beijing bohui innovation biotechnology group (300318.SZ) stated on the investor interaction platform that the company currently has no food safety related testing products.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The microfluidic chip used in the company's in vitro diagnostic test reagents is developed and manufactured by the company.
Gelonghui October 31st | Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interaction platform that the microfluidic chip used in the company's in vitro diagnostic test reagents is developed and manufactured by the company, mainly used as a liquid reagent carrier. It achieves the directional flow of liquid reagents in the chip through the pump valve driven by the instrument's gas path module, completing the sample extraction, PCR amplification, DNA reverse hybridization, and other detection processes. The microfluidic chip is used in conjunction with the company's detection analyzers to automate the detection of molecular diagnostic reagents.
Bohui Innovation: 2024 Third Quarter Report
beijing bohui innovation biotechnology group (300318.SZ) released net income for the first three quarters, with a net income of 23.7177 million yuan, an increase of 67.77%.
beijing bohui innovation biotechnology group (300318.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters was 6...
Beijing Bohui Innovation Biotechnology Group (300318.SZ): net income for the first three quarters was 23.7177 million yuan, a year-on-year increase of 67.77%.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced its third quarter report for 2024 on October 29. The company achieved revenue of 0.646 billion yuan in the first three quarters of the year, a year-on-year decrease of 19.85%; net income attributable to shareholders of the listed company was 23.7177 million yuan, a year-on-year increase of 67.77%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 15.6564 million yuan, a year-on-year increase of 29.24%; basic earnings per share were 0.0290 yuan.
